Patents by Inventor Zhengxia Chen

Zhengxia Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal form of azaindole derivative and use thereof
    Patent number: 11919898
    Abstract: A crystal form of an azaindole derivative and a preparation method thereof are disclosed.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: March 5, 2024
    Assignee: SHENZHEN LINGFANG BIOTECH CO., LTD.
    Inventors: Zhengxia Chen, Meibi Dai, Yang Zhang
  • CRYSTAL FORM OF AZAINDOLE DERIVATIVE AND USE THEREOF
    Publication number: 20230322760
    Abstract: A crystal form of an azaindole derivative and a preparation method thereof are disclosed.
    Type: Application
    Filed: January 15, 2021
    Publication date: October 12, 2023
    Applicant: Wuxi Life Fountain Biotech Co., Ltd
    Inventors: ZHENGXIA CHEN, MEIBI DAI, YANG ZHANG
  • TRIAZOLONE COMPOUND
    Publication number: 20230257362
    Abstract: The present invention discloses a series of triazolone compounds, and specifically discloses a compound and a pharmaceutically acceptable salt thereof as shown in formula (V).
    Type: Application
    Filed: May 24, 2021
    Publication date: August 17, 2023
    Inventors: Shuhui CHEN, Zhengxia CHEN
  • CRYSTALLINE FORM OF FLUVATINIB OR FLUVATINIB METHANESULFONATE AND PREPARATION METHOD THEREFOR
    Publication number: 20230106064
    Abstract: Disclosed in the present invention is a crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in FIG. 1. The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in FIG. 9. Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.
    Type: Application
    Filed: March 16, 2021
    Publication date: April 6, 2023
    Applicants: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD, YAOPHARMA CO., LTD.
    Inventors: Shuai HE, Yang ZHANG, Qiang LIU, Zhengxia CHEN, Meibi DAI, Bin FAN, Peiyu XIE
  • FUSED RING COMPOUND AS FGFR AND VEGFR DUAL INHIBITOR
    Publication number: 20220315581
    Abstract: A fused ring compound as an FGFR and VEGFR dual inhibitor. Particularly, disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 6, 2022
    Inventors: Zhengxia CHEN, Haizhong TAN, Yang ZHANG, Jian LI, Shuhui CHEN
  • Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof
    Patent number: 11440903
    Abstract: The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 13, 2022
    Assignees: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD
    Inventors: Chaofeng Long, Yang Zhang, Zhengxia Chen, Xiaoxin Chen, Zhuowei Liu, Meibi Dai, Zhiqiang Liu, Shuhui Chen
  • PYRIDINE DERIVATIVE AS FGFR AND VEGFR DUAL INHIBITORS
    Publication number: 20220267324
    Abstract: FGFR and VEGFR dual inhibitors, specifically being a compound represented by formula (I) or a pharmaceutically acceptable salt.
    Type: Application
    Filed: July 24, 2020
    Publication date: August 25, 2022
    Inventors: Zhengxia CHEN, Meibi DAI, Yang ZHANG, Shuhui CHEN
  • PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220220104
    Abstract: Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 3, 2020
    Publication date: July 14, 2022
    Applicants: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY, MEDSHINE DISCOVERY INC.
    Inventors: Jiansong WANG, Zhengxia CHEN, Zhibo LUO, Meibi DAI, Yang ZHANG, Shuhui CHEN, Yingxia BAO, Wei WANG, Zhoufan XIE
  • APPLICATION OF COMBINATION OF QUINOLINE DERIVATIVE AND IMMUNOMODULATOR IN PREPARATION OF ANTITUMOR DRUGS
    Publication number: 20220175756
    Abstract: Provided is an application of the combination of a quinoline derivative and an immunomodulator in preparation of antitumor drugs.
    Type: Application
    Filed: March 16, 2020
    Publication date: June 9, 2022
    Applicants: CHONGQING PHARMACEUTICAL INDUSTRIAL RESEARCH INSTITUTE CO., LTD., YAOPHARMA CO., LTD.
    Inventors: Yang ZHANG, Zhengxia CHEN, Jian LI, Shuhui CHEN
  • VINYLPYRIDINE CARBOXAMIDE COMPOUND AS PD-L1 IMMUNOMODULATOR
    Publication number: 20220144806
    Abstract: Disclosed is a PD-L1 inhibitor, and specifically disclosed is a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.
    Type: Application
    Filed: February 3, 2020
    Publication date: May 12, 2022
    Applicant: ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.,
    Inventors: Yang Zhang, Yuanfeng Xia, Zhengxia Chen, Meibi Dai, Deheng Sun, Jian Zuo, Jian Li, Shuhui Chen
  • FLUOROVINYLBENZAMIDE COMPOUND AS PD-L1 IMMUNOMODULATOR
    Publication number: 20220119368
    Abstract: The present invention relates to a PD-L1 immunomodulator, and specifically discloses a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.
    Type: Application
    Filed: February 3, 2020
    Publication date: April 21, 2022
    Applicant: ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.,Ltd
    Inventors: Yang Zhang, Yuanfeng Xia, Deheng Sun, Jian Zuo, Zhengxia Chen, Meibi Dai, Jian Li, Shuhui Chen
  • Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors
    Patent number: 11236094
    Abstract: Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 1, 2022
    Assignee: CSPC ZHONGQI PHARMACEUTICALL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
    Inventors: Yikai Wang, Yang Zhang, Zhengxia Chen, Linlin Chen, Tao Feng, Rongxin Huang, Qiu Li, Deyao Li, Jikui Sun, Yangyang Xu, Jie Li, Jian Li, Shuhui Chen
  • Quinoline derivative and use thereof as tyrosine kinase inhibitor
    Patent number: 11161817
    Abstract: A quinoline derivative compound shown in formula (II), a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to a tyrosine kinase inhibitor.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: November 2, 2021
    Assignees: CHONGQING PHARMACEUTICAL INDUSTRIAL RESEARCH INSTITUTE CO. LTD., YAOPHARMA CO., LTD.
    Inventors: Yang Zhang, Zhengxia Chen, Meibi Dai, Wenju Li, Jian Li, Shuhui Chen
  • AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR
    Publication number: 20210253571
    Abstract: A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 19, 2019
    Publication date: August 19, 2021
    Inventors: Yang ZHANG, Zhengxia CHEN, Yikai WANG, Meibi DAI, Jie LI, Zhen GONG, Jian LI, Shuhui CHEN
  • Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor
    Patent number: 11078194
    Abstract: Disclosed in the present invention are a salt form and a crystal form serving as FGFR and VEGFR inhibitor compounds, a preparation method therefor, and medical uses thereof.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 3, 2021
    Assignee: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Zhengxia Chen, Yang Zhang, Meibi Dai, Hongfei Cheng, Suqin Yang, Wenju Li, Jian Li, Shuhui Chen
  • FGFR4 inhibitor and preparation method and use thereof
    Patent number: 11008292
    Abstract: Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 18, 2021
    Inventors: Zhengxia Chen, Chaofeng Long, Yang Zhang, Xiaoxin Chen, Yikai Wang, Meibi Dai, Zhuowei Liu, Haixia Zhao, Xing Liu, Guoping Hu, Jian Li, Shuhui Chen
  • SALT FORM AND CRYSTAL FORM OF COMPOUND AS FGFR4 INHIBITOR AND PREPARATION METHOD THEREOF
    Publication number: 20210087181
    Abstract: The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.
    Type: Application
    Filed: October 30, 2018
    Publication date: March 25, 2021
    Applicants: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD
    Inventors: Chaofeng LONG, Yang ZHANG, Zhengxia CHEN, Xiaoxin CHEN, Zhuowei LIU, Meibi DAI, Zhiqiang LIU, Shuhui CHEN
  • SALT FORM AND CRYSTAL FORM SERVING AS FGFR AND VEGFR INHIBITOR COMPOUNDS, AND PREPARATION METHOD THEREFOR
    Publication number: 20200361913
    Abstract: Disclosed in the present invention are a salt form and a crystal form serving as FGFR and VEGFR inhibitor compounds, a preparation method therefor, and medical uses thereof.
    Type: Application
    Filed: December 7, 2018
    Publication date: November 19, 2020
    Inventors: Zhengxia CHEN, Yang ZHANG, Meibi DAI, Hongfei CHENG, Suqin YANG, Wenju LI, Jian LI, Shuhui CHEN
  • Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
    Patent number: 10766862
    Abstract: Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 8, 2020
    Assignee: Guangdong Raynovent Biotech Co., Ltd.
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Shuhui Chen, Jian Li
  • QUINOLINE DERIVATIVE AND USE THEREOF AS TYROSINE KINASE INHIBITOR
    Publication number: 20200262791
    Abstract: A quinoline derivative compound shown in formula (II), a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to a tyrosine kinase inhibitor.
    Type: Application
    Filed: September 20, 2018
    Publication date: August 20, 2020
    Inventors: Yang ZHANG, Zhengxia CHEN, Meibi DAI, Wenju LI, Jian LI, Shuhui CHEN